International Clinical Trial: A Study on Predicting the Efficacy of Neoadjuvant Immunotherapy for Stage II-III Resectable Non-Small Cell Lung Cancer Based on Spatial Heterogeneity of PD-L1 Expression

Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118367) titled 'A Study on Predicting the Efficacy of Neoadjuvant Immunotherapy for Stage II-III Resectable Non-Small Cell Lung Cancer Based on Spatial Heterogeneity of PD-L1 Expression' on Feb. 4.

Study Type: Observational study

Study Design: Sequential

Primary Sponsor: Henan Provincial People's Hospita,medical

Condition: EGFR/ALK negative stage II-III non-small cell lung cancer

Intervention: Primary foci in the lung group:None

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2025-07-10

Target Sample Size: Primary foci in the lung group:400;Metastatic lymph node group:100;

Countries of Recruit...